Norway Wants to Lead Clinical Research. Here Is One Test.

The candidate

DemeRx is developing DMX-1001, oral noribogaine, as an investigational treatment for alcohol use disorder (AUD). ClinicalTrials.gov records a completed Phase 1 multiple-ascending-dose study in 55 healthy volunteers. DemeRx separately reports that the U.S. FDA accepted an Investigational New Drug application in 2026. Those are development milestones, not proof of clinical efficacy in people with AUD.

The right stance at this stage is therefore neither enthusiasm nor dismissal. It is disciplined uncertainty: the molecule has progressed far enough to justify serious clinical-development questions, while the central efficacy questions remain exactly that — questions.

Why Norway, now?

Norway's National Action Plan for Clinical Studies and Clinical Research 2026–2036 sets a striking target: Norway should be among the top three countries in Europe for clinical studies per million inhabitants. The plan also calls for stronger collaboration with industry, more research capacity, and better use of digital infrastructure and health data.

NorTrials already provides a national gateway for companies and investigators seeking to assess clinical-trial opportunities in Norwegian hospitals. Its role is not to fund a sponsor's development programme or lower scientific standards. Its value is that feasibility can be tested through an existing national pathway rather than through improvised lobbying.

That creates a narrow window worth examining. Norway has publicly committed to becoming better at exactly the activity DMX-1001 now needs: rigorous clinical evaluation.

The scale of the problem is not marginal. Norwegian authorities cite annual socioeconomic costs associated with alcohol use of roughly NOK 80–100 billion. That figure does not validate any particular treatment candidate, but it does put the value of rigorous treatment research in perspective.

This is not a campaign for approval

I have previously corresponded with DemeRx about Norway as a possible setting for alcohol-related clinical development. The practical barriers discussed were not mystical: financing, clinical partners and navigation of the Norwegian system.

I subsequently mapped a preliminary route involving sponsor-led development, a serious Norwegian principal investigator and site, NorTrials feasibility, the normal EU/EEA clinical-trial pathway, and clearly separated Norwegian research or health-economic layers where legitimate public funding might be relevant.

That map may be wrong. Parts of it almost certainly need correction by people who actually run trials. That is precisely why I am making the question public.

The proposal is not: fund this drug because I believe in it.

The proposal is: test whether Norway can assemble the scientific, clinical, operational and financing conditions required to evaluate it properly — and be willing to conclude no if the case fails.

What would a serious feasibility test ask?

A useful feasibility process should make it easier to kill a weak idea early, not merely make it easier to promote a strong-sounding one.

• Is there a Norwegian investigator and site with credible AUD/addiction-trial competence and genuine interest?
• Is recruitment plausible for the intended protocol and population?
• Can pharmacy, investigational-product handling, monitoring and CTIS requirements be met without creating an artificial local pathway?
• Which costs are unambiguously the sponsor's responsibility, and which independent Norwegian research questions could legitimately be co-funded?
• What safety, efficacy, operational or economic evidence would make Norway a no-go?

Why this belongs inside Human Autonomy Study

HAS began with a narrower question: how is human autonomy rebuilt when capacity is low? Recovery made that question unavoidable for me.

One lesson has become increasingly important: lived experience is valuable for identifying failure modes and generating better questions, but it cannot be allowed to become a substitute for evidence.

That principle scales. A person who has lived through addiction can point to where treatment systems fail, what outcomes matter, and what questions clinicians or researchers may be overlooking. The answer still has to survive scientific scrutiny.

DMX-1001 is therefore useful to HAS not as a product to endorse, but as a live test of a larger idea: can lived experience, research infrastructure, industry and public systems interact without collapsing their different roles?

The commitment is already on the table

Norway has already made the commitment: become one of Europe’s leading countries for clinical research, increase participation, attract more industry investment, and make studies faster to initiate and conduct. At the same time, alcohol use carries an estimated socioeconomic cost of NOK 80–100 billion a year.

None of that proves that DMX-1001 works. It does make one position harder to defend: ambitious research targets, an enormous unresolved burden, and a concrete, falsifiable proposal sitting openly in front of us — without anyone seriously testing whether the pieces can be connected.

The proposal is now public. The assumptions are visible. The weak points can be attacked. The pathway can be corrected or rejected.

So the next step does not require belief in DMX-1001. It requires someone qualified to tell us, precisely, where this fails — or help test whether it does not.

An invitation to disagree usefully

I would especially like to hear from addiction researchers, clinical-trial investigators, pharmacologists, trial operations specialists, health economists, people with lived experience, and skeptics.

If this is a poor fit for Norway, I want to know why. If the financing logic is naive, show me where. If the clinical pathway is unrealistic, identify the bottleneck. If there is a credible route, help define the minimum evidence and partners required before anyone spends serious money or political capital.

That is a better use of disagreement than asking people to join a side.